Oragenics Inc. stock is down -1.87% since 30 days ago. The next earnings date is Apr 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 21.43% of the previous 13 December’s closed higher than November.
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. NT-CoV2-1, an intranasal vaccine candidate provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.